Immuneering (IMRX) Earnings Date & Reports

Key Takeaways

• Consensus EPS estimate stands at -$0.27 for the second quarter, representing a meaningful improvement from -$0.40 reported in Q2 2025.
• No revenue is expected, consistent with Immuneering's status as a pre-commercial, clinical-stage oncology company.
• Earnings beat momentum: IMRX has surpassed consensus EPS estimates in three of its last four quarterly reports, including a 30% beat in Q1 2026.
• Cash runway remains a strength: The company ended Q1 2026 with $198.6 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2029.
• Clinical catalysts are stacking up: The pivotal Phase 3 MAPKeeper 301 trial for lead candidate atebimetinib is recruiting, with first patient dosing on track for mid-2026.
• Stock under pressure: Shares are down roughly 37% year-to-date, trading near $4.64, well below the average analyst price target of approximately $17.

Earnings Context and Why It Matters

Immuneering Corporation (NASDAQ: IMRX) is scheduled to report its second-quarter 2026 financial results before the market opens on Tuesday, August 12. As a late-stage clinical oncology company with no approved products, Immuneering's quarterly earnings serve less as a gauge of commercial performance and more as a checkpoint on cash management, pipeline advancement, and operational discipline. Investors and analysts will be closely watching for updates on the company's lead Deep Cyclic Inhibitor candidate, atebimetinib, which recently delivered a median overall survival (OS) of 17.3 months in a Phase 2a pancreatic cancer study — more than double the historical benchmark for standard chemotherapy. With the Phase 3 MAPKeeper 301 trial now recruiting and fresh ASCO (American Society of Clinical Oncology) data still resonating, this earnings report arrives at a pivotal moment for the company's pipeline narrative.

Earnings Expectations

Wall Street expects Immuneering to report a net loss of approximately $0.27 per share for the second quarter of 2026, according to consensus estimates tracked by MarketWatch and TipRanks. Individual analyst projections range from a loss of $0.24 to $0.31 per share. This would mark a notable improvement from the $0.40 per-share loss reported in the same period a year ago, reflecting disciplined cost management and a shift in clinical spending toward the lead atebimetinib program. Revenue is universally forecast at zero dollars, given the company's pre-commercial stage. Immuneering has a strong track record of earnings beats: Q1 2026 came in at -$0.21 versus a -$0.30 consensus (a 30% positive surprise), Q4 2025 delivered -$0.18 against -$0.31 expectations (a 42% beat), and Q3 2025 was essentially in line. The only miss in the last five quarters occurred in Q1 2025. Investors will also monitor research and development (R&D) expenses, which were $10.6 million in Q1 2026, and general and administrative (G&A) expenses, which totaled $4.7 million, for signs of sustained operational efficiency.

AI Screener

For investors seeking to identify opportunities in the volatile biotechnology sector or beyond, Tickeron's AI Screener offers a powerful solution. This AI-powered stock and ETF (exchange-traded fund) discovery tool enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, and AI-driven signals. Whether scanning for breakout candidates, trend-following setups, or fundamentally undervalued names, the AI Screener streamlines the research process and surfaces ideas that manual screening might overlook. As earnings season unfolds, tools like this can help market participants stay ahead of key reporting dates and emerging sector momentum. Explore the AI Screener to see how data-driven filtering can sharpen your market perspective.

Market Reaction and Investor Sentiment

Sentiment heading into the Q2 2026 print is mixed, reflecting both clinical promise and market skepticism. Despite a broadly bullish analyst consensus — with seven firms rating IMRX a Strong Buy and an average price target near $17 — the stock has struggled to find upward traction, hovering around $4.64 and down approximately 37% year-to-date. A notable "sell the news" reaction followed the ASCO 2026 presentation of atebimetinib's 17.3-month median OS data, with shares dropping roughly 23% in a single session amid profit-taking after a prior rally. On the other hand, insider buying activity has been visible, with CEO Benjamin Zeskind and other executives acquiring shares in recent months. Key risk factors heading into the report include any signs of accelerating cash burn tied to the Phase 3 trial ramp-up, potential delays in patient enrollment, and broader biotech sector headwinds. The Q2 earnings call's tone on clinical timelines will likely matter more to the stock's near-term trajectory than the headline EPS figure itself.

Forward Outlook and Key Factors to Monitor

Looking beyond the second-quarter release, Immuneering's investment case hinges almost entirely on clinical execution. The most consequential near-term milestone is the dosing of the first patient in the pivotal Phase 3 MAPKeeper 301 trial, which management expects to achieve by mid-2026. An update confirming this milestone — or signaling any deviation from the timeline — will be among the most closely scrutinized details on the earnings call.

Equally important is the planned initiation of a Phase 2 trial evaluating atebimetinib in combination with Regeneron's Libtayo (cemiplimab) for first-line RAS-mutant non-small cell lung cancer (NSCLC), expected in the second half of 2026. Progress on this front would validate the drug's potential beyond pancreatic cancer and into larger oncology markets.

On the financial side, investors should track whether the $198.6 million cash position remains sufficient to reach the company's stated 2029 runway target, particularly as Phase 3 trial costs escalate. The appointment of veteran biotech CFO Andrew Gengos in July 2026 also signals a focus on financial stewardship and potential future partnering or financing discussions. With top-line Phase 3 data from MAPKeeper 301 not expected until mid-2028, the quarters ahead will be defined by operational milestones, enrollment updates, and Immuneering's ability to maintain momentum across a broadening clinical pipeline. As always with pre-revenue biotechs, the balance between ambition and cash conservation remains the central narrative.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations